Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

An,Elderly,Person,With,Highlighted,Brain.,Dementia,,Conceptual,3d,Illustration

On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD-GRN).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.